Grafapex vs Rhapsido
A plain-English comparison of two oncology drugs that may be accessible via NPP.
Side-by-side
| Grafapex | Rhapsido | |
|---|---|---|
| Generic name | treosulfan | remibrutinib |
| Manufacturer | medac GmbH (US commercial rights: Medexus) | Novartis |
| Modality | Alkylating-agent injection (in combination with fludarabine) | Oral BTK inhibitor (tablet, twice daily) |
| Indication | Hematology/oncology (transplant conditioning) | Dermatology / allergy (chronic spontaneous urticaria) |
| FDA approval | January 21, 2025 | September 30, 2025 |
When physicians choose Grafapex
Grafapex is typically selected when its mechanism and labeled indication fit the disease subtype. It is manufactured by medac GmbH (US commercial rights: Medexus) and represents an Alkylating-agent injection (in combination with fludarabine) option in Hematology/oncology (transplant conditioning).
When physicians choose Rhapsido
Rhapsido is typically selected when its mechanism aligns better with disease sub-type, prior therapy failure, or safety profile. It is manufactured by Novartis and represents an Oral BTK inhibitor (tablet, twice daily) option in Dermatology / allergy (chronic spontaneous urticaria).
Both drugs - access via NPP
Both Grafapex and Rhapsido can be accessed via NPP in most of our covered markets. Choice between them is a clinical decision for the treating physician.
Not medical advice
This comparison is information, not clinical guidance.
Request either drug
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).